B. Braun Medical Inc. (B. Braun), a prominent leader in the field of intelligent infusion therapy and pain management, has announced its receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the AQUAbase nX Reverse Osmosis System.

The AQUAbase nX stands as a single-stage reverse osmosis apparatus designed to deliver top-notch water quality for dialysis patients, all without the necessity of using chemicals. Thanks to its innovative design, the AQUAbase nX boasts an impressive raw water conversion rate of up to 75%, potentially leading to water conservation and cost reduction in terms of power, pre-treatment, and equipment maintenance.

Jonathan Stapley, Senior Director of Marketing, Active Devices, expressed enthusiasm, stating, "We are thrilled to enhance our array of high-quality hemodialysis products with the AQUAbase nX. This compact solution is ideal for smaller facilities, offering heat disinfection to reduce the reliance on chemical agents."

The system features a complete stainless steel piping system designed to minimize dead space in the primary loop, potentially preventing microbial contamination. With a range of system capacities from 250 L/h to 750 L/h, the AQUAbase nX serves as a versatile and customizable solution for hospitals, dialysis centers, or skilled nursing facilities with five to 18 chairs for dialysis patients. The system's seven-inch touchscreen display allows for easy access to relevant settings and provides real-time status updates.

 

Source: prnewswire.com

Report Abuse